Culture Council

Understanding the Regulatory Greenscape in 2024

The FDA’s recommendation to classify cannabis as Schedule III contained in a 252-page reportwas sent to the U.S. Drug Enforcement Administration (DEA) in August 2023. The FDA assessed medical efficacy use in seven indications: anorexia, anxiety, epilepsy, inflammatory bowel disease, nausea and vomiting, pain, and posttraumatic stress disorder. The report …

Read More »

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news